Joint development of a tau protein assay system and expansion into in vitro diagnostic products
First written in FY2018-Q1. 2 of 4 entries say "Advanced", first in FY2018-Q3. Latest entry: FY2020.
No other company in this theme has enough history to compare yet.
- FY2020AdvancedAnnual report
「The company released the in vitro diagnostic products “Tau Protein-IBL” and “pTau Protein-IBL” on 7 November 2019.」
The tau and phosphorylated tau assay systems progressed from overseas sales as research reagents to the release of in vitro diagnostic drugs. - FY2019RestatedAnnual report
「We developed assay kits for tau and phosphorylated tau proteins and began selling them overseas as research reagents. We will also continue development as in vitro diagnostic drugs in Japan.」
The policy of selling tau and phosphorylated tau assay kits overseas as research reagents and developing them as in vitro diagnostic drugs in Japan remains unchanged. - FY2018-Q3AdvancedAnnual report
「We had been jointly developing an assay system for tau protein, an important target molecule alongside amyloid beta among dementia-related proteins, with an overseas diagnostic company, but first began selling it overseas as a research reagent.」
The tau protein assay system progressed from the development stage to the launch of sales as a research reagent overseas. - FY2018-Q1First statedAnnual report
「We are jointly developing an assay system for tau protein with an overseas diagnostic company. Tau is an important target molecule, alongside amyloid beta, among dementia-related proteins. Because the product is expected to generate synergies with the amyloid beta product currently on the market, we will aim for an early launch. We are also pursuing development as an in vitro diagnostic drug in Japan.」
The company is developing a tau protein assay system jointly with an overseas diagnostic company, with the aim of selling it together with existing amyloid beta products and developing it as an in vitro diagnostic drug in Japan.